Although TNF-related apoptosis-inducing ligand (TRAIL) usually induces cell death in tumor cells, there are some tumor cell types that are resistant to its apoptogenic effects. Some chemotherapeutic drugs, however, can sensitize resistant cancer cells to TRAIL by either upregulating surface TRAIL death receptor expression or by modulating intracellular signalling pathways emanating from TRAIL receptors. U2OS human osteosarcoma cells express TRAIL-R2 but are resistant to TRAIL-induced apoptosis. However, the genotoxic drugs, Doxorubicin and Cisplatin, are able to sensitize U20S cells to TRAIL, without affecting their surface expression of either death or decoy TRAIL receptors. We demonstrate that Doxorubicin and Cisplatin downmodulate X-IAP, while not affecting FLIP levels in U20S cells. Selective downmodulation of X-IAP protein synthesis by specific small interference RNA transfection induced a sensitization of U20S cells to TRAIL comparable to that induced by pharmacological treatment with genotoxic drugs. TRAIL-R2 downmodulation by siRNAs completely abolished the TRAIL-induced apoptosis of genotoxin-treated U20S cells. Our findings demonstrate that Doxorubicin and Cisplatin do not sensitize U20S osteosarcoma cells to TRAIL by surface receptor modulation but rather by the removal of the intracellular signalling inhibition generated by X-IAP, suggesting a foreseeable relevant advantage to the therapy of these tumors by the combined regimen of genotoxin-based chemotherapy and TRAIL.

Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins / Mirandola, P; Sponzilli, I; Gobbi, G; Marmiroli, Sandra; Rinaldi, L; Binazzi, R; Piccari, Gg; Ramazzotti, G; Gaboardi, Gc; Cocco, L; Vitale, M.. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - STAMPA. - 28:1(2006), pp. 127-133. [10.3892/ijo.28.1.127]

Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.

MARMIROLI, Sandra;
2006

Abstract

Although TNF-related apoptosis-inducing ligand (TRAIL) usually induces cell death in tumor cells, there are some tumor cell types that are resistant to its apoptogenic effects. Some chemotherapeutic drugs, however, can sensitize resistant cancer cells to TRAIL by either upregulating surface TRAIL death receptor expression or by modulating intracellular signalling pathways emanating from TRAIL receptors. U2OS human osteosarcoma cells express TRAIL-R2 but are resistant to TRAIL-induced apoptosis. However, the genotoxic drugs, Doxorubicin and Cisplatin, are able to sensitize U20S cells to TRAIL, without affecting their surface expression of either death or decoy TRAIL receptors. We demonstrate that Doxorubicin and Cisplatin downmodulate X-IAP, while not affecting FLIP levels in U20S cells. Selective downmodulation of X-IAP protein synthesis by specific small interference RNA transfection induced a sensitization of U20S cells to TRAIL comparable to that induced by pharmacological treatment with genotoxic drugs. TRAIL-R2 downmodulation by siRNAs completely abolished the TRAIL-induced apoptosis of genotoxin-treated U20S cells. Our findings demonstrate that Doxorubicin and Cisplatin do not sensitize U20S osteosarcoma cells to TRAIL by surface receptor modulation but rather by the removal of the intracellular signalling inhibition generated by X-IAP, suggesting a foreseeable relevant advantage to the therapy of these tumors by the combined regimen of genotoxin-based chemotherapy and TRAIL.
28
1
127
133
Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins / Mirandola, P; Sponzilli, I; Gobbi, G; Marmiroli, Sandra; Rinaldi, L; Binazzi, R; Piccari, Gg; Ramazzotti, G; Gaboardi, Gc; Cocco, L; Vitale, M.. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - STAMPA. - 28:1(2006), pp. 127-133. [10.3892/ijo.28.1.127]
Mirandola, P; Sponzilli, I; Gobbi, G; Marmiroli, Sandra; Rinaldi, L; Binazzi, R; Piccari, Gg; Ramazzotti, G; Gaboardi, Gc; Cocco, L; Vitale, M.
File in questo prodotto:
File Dimensione Formato  
Int J Oncol Vol28 No1 Pg127.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 307.29 kB
Formato Adobe PDF
307.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/455592
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 41
social impact